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Abstract
Drug repositioning is an attractive cost-efficient strategy for the development of
treatments for human diseases. Here, we propose an interpretable model that
learns disease self-representations for drug repositioning. Our self-representation
model represents each disease as a linear combination of a few other diseases.
We enforce proximity in the learnt representations in a way to preserve the geo-
metric structure of the human phenome network — a domain-specific knowledge
that naturally adds relational inductive bias to the disease self-representations. We
prove that our method is globally optimal and show results outperforming state-
of-the-art drug repositioning approaches. We further show that the disease self-
representations are biologically interpretable.
1 Introduction
New drug discovery and development presents several challenges including high attrition rates, long
development times, and substantial costs [Ashburn and Thor, 2004]. Drug repositioning, the process
of finding new therapeutic indications for already marketed drugs, has emerged as a promising
alternative to new drug development. It involves the use of de-risked compounds in human, which
translates to lower development costs and shorter development times [Pushpakom et al., 2018].
A wide range of computational approaches has been proposed to predict novel indications for exist-
ing drugs. The common assumption underlying these methods is that there is biological or pharma-
cological relational information between drugs, e.g., chemical structure, and between diseases, e.g.,
disease phenotypes, that can be exploited for the prediction task. Current methods typically rely
on well-defined heuristics and/or hand-crafted features. For instance, the PREDICT [Gottlieb et al.,
2011] model extracts drug-disease features from multiple similarity measures, and then trains a
logistic regression classifier to predict novel drug indications. Similarly, [Napolitano et al., 2013]
obtains features from heterogeneous drug similarity measures and then trains an SVM classifier
to predict therapeutic indications of drugs. Other approaches include random walks on bipartite
networks [Luo et al., 2016], and low-rank matrix completion-based approaches [Luo et al., 2018].
In this paper, we propose a self-representation learning model for drug repositioning that is able to
overcome the limitations of heuristic-based approaches and extend the expressiveness of low-rank
factorisation models for matrix completion. Our model builds upon the recent development of high-
rank matrix completion based on self-expressive models (SEM) [Elhamifar, 2016], as well as the
recent trend of deep learning on graphs [Bronstein et al., 2017, Monti et al., 2017, Hamilton et al.,
2017]. We propose a geometric SEM model that integrates relational inductive bias about genetic
diseases in the form of a disease phenotype similarity graph. Extensive experiments on a standard
benchmark dataset show that our method outperforms existing state-of-the-art approaches in drug
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repositioning, and that the inclusion of relational inductive bias significantly improves the perfor-
mance while enhancing model interpretability.
2 Geometric Self-Expressive Models (GSEM)
2.1 Regularisation Framework
The goal of self-expressive models (SEM) is to represent datapoints, i.e., diseases, approximately as
a linear combination of a small number of other datapoints. Proposed as a framework for simulta-
neously clustering and completing high-dimensional data lying over the union of low-dimensional
subspaces [Fan and Chow, 2017, Wang and Elhamifar, 2018], these models can effectively gener-
alise standard low-rank matrix completion models. Here we cast drug repositioning as a high-rank
matrix completion task and propose a model that naturally extends SEM by imposing a relational in-
ductive prior between datapoints. Because of the geometrical structure enforced between datapoints,
we refer to our model as Geometric SEM (GSEM).
Let us denote our drug disease matrix for n drugs and m diseases with the matrix X ∈ Rn×m
(each column is a datapoint) where xij = 1 if drug i is associated with disease j, and zero otherwise.
GSEM aims at learning a sparse zero-diagonal self-representationmatrixC ∈ Rm×m of coefficients
for diseases such that Xˆ ≈ XC, where the null diagonal aims at ruling out the trivial solutionC = I .
To this end, we minimise the following cost function:
min
C≥0
1
2
‖X −XC‖2F︸ ︷︷ ︸
self-representation
+
β
2
‖C‖2F + λ‖C‖1︸ ︷︷ ︸
sparsity
+
α
2
‖C‖2D,G︸ ︷︷ ︸
smoothness
+ γ Tr(C)︸ ︷︷ ︸
null diagonal
(1)
where ‖.‖F denotes the Frobenius norm, and ‖C‖D,G the Dirichlet norm on the graph G =
({1, . . . ,m}, E ,W ), i.e., the weighted undirected graph with edge weights wij > 0 if (i, j) ∈ E
and zero otherwise, representing the similarities between diseases. We further denote the cost func-
tion in Eq. (1) by Q(C). The first term in Eq. (1) is the self-representation constraint, which aims
at learning a matrix of coefficients C such that XC is a good reconstruction of the original matrix
X . The second term is the sparsity constraint, which uses the elastic-net regularisation known to
impose sparsity and grouping-effect [Ng, 2004, Zou and Hastie, 2005]. The fourth term is a penalty
for diagonal elements to prevent the trivial solution C = I by imposing diag(C) = 0 (together with
C ≥ 0). Typically, γ ≫ 0 is used. Relational inductive bias between diseases is imposed by the
third smoothness term in Eq.1 [Ma et al., 2011, Kalofolias et al., 2014, Monti et al., 2017], incorpo-
rating geometric structure into the self-representation matrix C from the disease-disease similarity
graph G. Ideally, nearby points in G should have similar coefficients in C, which can be obtained by
minimising: ∑
i,j
Gij‖ci − cj‖
2 = Tr(CLCT ) = ‖C‖2D,G (2)
where ci and cj represent column vectors of C and L = D − W is the graph Laplacian. The
parameter α > 0 in Eq.1 weighs the importance of the smoothness constraint for the prediction.
Finally, to favour interpretability of the learned self-representations, we followed [Lee and Seung,
1999] and also imposed a non-negativity constraint on C.
2.2 The multiplicative learning algorithm
To minimise Eq. 1, we developed an efficient multiplicative learning algorithm with theoretical
guarantees of convergence. Our algorithm consists in iteratively applying the following rule:
cij ← cij
(X⊤X + αCW )ij
(X⊤XC + αCD + βC + λ+ γI)ij
(3)
We shall prove that the cost functionQ(C) is convex and therefore, our multiplicative rule in Eq. (3)
converges to a global minimum.
2
Lemma 1. The cost functionQ(C) in Eq. 1 is convex in the feasible region C ≥ 0.
Proof Sketch. We need to prove that the Hessian is a positive semi-definite (PSD) matrix. That is, for
a non-zero vector h ∈ Rm the following condition is met hT∇2Q(C)h ≥ 0. The graph Laplacian
is PSD by definition. The remaining terms in the Hessian (X⊤X + βI) are also PSD. Therefore,
Q(C) is convex in C ≥ 0.
Theorem 1 (Convergence). The cost functionQ(C) in Eq. (1) converges to a global minimum under
the multiplicative update rule in (3).
Proof. We need to show that our algorithm satisfies the Karush-Khun-Tucker (KKT) complementary
conditions, which are both necessary and sufficient conditions for a global solution point given the
convexity of the cost function (lemma 1) [Li and Ding, 2006, Boyd and Vandenberghe, 2004]. KKT
requires cij ≥ 0 and (∇Q(C))ijcij = 0. The first condition holds with non-negative initialisation
of C. For the second condition, the gradient is: ∇Q(C) = −X⊤X − αCW +X⊤XC + αCD +
βC + λ + γI , and according to the second KKT condition, at convergence C = C∗ we have
(X⊤XC∗ + αC∗D + βC∗ + λ+ γI)ijc
∗
ij − (X
⊤X + αC∗W )ijc
∗
ij = 0, which is identical to (3).
That is, the multiplicative rule converges to a global minimum solution point.
3 Experimental Results
Datasets Drug-disease associations were obtained from the PREDICT dataset [Gottlieb et al.,
2011], a standard benchmark for computational drug repositioning. Our drug-disease matrix X
contains 1933 known drug-disease associations between 593 drugs (rows) and 313 genetic diseases
(columns). Drugs were extracted from the DrugBank database [Wishart et al., 2018] while diseases
were defined using the Online Mendelian Inheritance in Man (OMIM) database [Hamosh et al.,
2004]. To build the disease-disease graph G, we used the phenotypic disease similarity constructed
by [Van Driel et al., 2006]. Our adjacency matrixW consists of a dense matrix of 313 × 313 with
values ranging in the interval [0, 1].
Settings Following previous approaches [Gottlieb et al., 2011, Luo et al., 2018], we frame the
computational drug repositioning task as a binary classification problem. We used a ten-fold cross-
validation procedure while ensuring that all the drugs had at least one association in the training set.
For each fold, we used a validation set for hyperparameter tuning (λ, β, α and γ). To filter irrelevant
relationships between diseases, we also optimised a threshold parameter τ such that wij = 0 if
wij < τ . Given that our data matrixX is highly imbalanced (1.04% density), we measured the per-
formance of the classifier using the area under the precision recall curve (AUPR) — which has been
shown to be more informative than the AUROC in imbalanced scenarios [Saito and Rehmsmeier,
2015] — for varying values of ratio between negative (0s) and positive (1s) labels. We compared
the performance of our method against PREDICT [Gottlieb et al., 2011], a recent low-rank matrix
completion model called Drug Repositioning Recommendation System (DRRS) [Luo et al., 2018]
and a non-geometric version of our model (with α = 0, SEM). For both PREDICT and DRRS, we
ran the algorithms with the respective similarity measures used in their original papers. An object-
oriented implementation of our model, along with datasets to reproduce our study, is available at
https://github.com/Noired/GSEM.git.
Performance Evaluation Figure 1 summarises the performance of the methods. We observed that
while GSEM is only marginally better than DRRS and PREDICT in the balanced scenario (negative-
to-positive ratio 1:1, AUPR of 0.950 ± 0.010 for GSEM, 0.947 ± 0.012 for DRRS and 0.932 ±
0.020 for PREDICT), it greatly outperforms these competitors in imbalanced scenarios (by 1.0-
13.16% at 10:1, 4.67-29.15%at 30:1, 6.48-27.60%at 50:1 and 10.31-33.12%at 100:1). Although
PREDICT integrates information from seven heterogeneous similarity measures, it performs poorly
with high data imbalance, where, a simple SEM model, which does not use any relational prior
between diseases, intriguingly outperforms PREDICT and DRRS by 1.93-23.05% at 50:1 and 6.03-
28.84% at 100:1. This means that our high-rank model of X based on self-representations is able
to better exploit the intrinsic relationships between diseases inferred from the data matrix X —
we checked that indeed the matrix X has a high-rank (rank = 238/313). The contribution of the
relational information between diseases becomes clear when comparing the performances of the
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GSEM versus SEM model: on average, GSEM outperforms SEM by 4.85% AUPR across all the
ratios.
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Figure 1: (a) Drug repositioning performance. Mean and standard deviation for AUPR met-
ric computed using ten-fold cross-validation for varying values of negative to positive label ratios
(ratio∈ {1, 5, 10, 15, 20, 30, 40, 50, 100}). Performance of our method (GSEM) is reported, along
with that of the state-of-the-art DRRS [Luo et al., 2018], PREDICT [Gottlieb et al., 2011] and stan-
dard SEM. Our model performs best in the more realistic unbalanced scenario. (b) Model interpre-
tation. Comparative violin plot of disease self-representation similarities. Diseases were grouped
by well-known phenotypic classes. Significance levels between the average intra-class similarities
for GSEM and SEM is indicated with asterisks (p ≤ 0.001, ∗ ∗ ∗).
4 Model Interpretation
The effectiveness of our model at predicting new disease indications for drugs prompted us to anal-
yse whether the disease self-representations are informative of the biology underlying drug activity.
We assessed model interpretability by exploring the extent to which disease self-representations
were related to well-known disease classes. We retrieved disease classes from the International Clas-
sification of Diseases of the World Health Organization (WHO) (ICD10CM [WHO, 2016]). We
only kept diseases belonging to a unique class, and filtered diseases belonging to a class with less
than 5 diseases. For 182 diseases, we obtained 11 distinct classes (see Supplementary Materials).
We then defined a disease-disease similarity as the cosine similarity of the rows of S = (C+CT )/2.
For these experiments, we trained our model using all the available data in X and fixed optimal
hyper-parameters (see Supplementary Material). Figure 1(b) shows the violin plots of the distribu-
tion of similarities for diseases belonging to the same class (intra-class) versus diseases belonging
to distinct classes (inter-class), for both GSEM and SEM. We observed that for both GSEM and
SEM, the intra-class similarity is significantly higher than the inter-class similarity (Wilcoxon Sum
Rank Significance, p < 3.62 × 10−107 and p < 3.55 × 10−249 for SEM and GSEM, respectively),
meaning that both models learn biologically meaningful self-representations for diseases. However,
the intra-class disease self-representation similarity is significantly higher for GSEM than for SEM
(Wilcoxon Sum Rank Significance, p < 1.23 × 10−174), suggesting that our geometric model ef-
ficiently integrates the relational phenotypic information between diseases encoded in the human
phenome network.
5 Conclusions and Future Work
Inherently interpretable models are critical for applications involving high-stakes decisions such as
health care [Rudin, 2019]. These are unfeasible to achieve with neural nets, because the learned rep-
resentations depend on uninterpreted features in other layers [Hinton, 2018]. Here we proposed an
inherently interpretable model, GSEM, that learns self-representations for diseases. Our model ef-
fectively integrates the relational inductive bias from the human phenome network [Van Driel et al.,
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2006] — better results could possibly be achieved using the [Caniza et al., 2015] disease sim-
ilarity, which has shown to be effective for the prediction of genes associated to genetic dis-
eases [Cáceres and Paccanaro, 2019]. Ongoing research includes the integration of relational in-
ductive bias for drugs as well.
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6 Supplementary Material
6.1 Model Implementation
PREDICT We re-implemented the PREDICT algorithm in Python 3.6. We computed seven drug-
disease features using the original data and following the procedure in [Gottlieb et al., 2011]. To
train the model, we used the LogisticRegression classifier from sklearn.linear_model to
obtain the scores for the drug-disease pairs.
DRRS To run Drug Repositioning Recommender System [Luo et al., 2018], we used the data and
code provided in the original publication2. DRRS uses two complementary information for the
prediction: the 2D Tanimoto chemical similarity for drugs and phenotype similarities for diseases
obtained from MimMiner [Van Driel et al., 2006].
GSEM We implemented our proposed algorithm in Python 3.6. As model learning is
based on a multiplicative learning rule similar to that of non-negative matrix factorisation
(NMF) [Lee and Seung, 1999, 2001], we followed the recommended guidelines in [Berry et al.,
2007] to implement it: (i) C was initialised with weights sampled from a uniform distribution be-
tween [0, b), with b = 1 × 10−2; (ii) a small value ε ≃ 1 × 10−16 was added to the denominator
of the learning algorithm to prevent division by zero. The learning rule is iteratively applied un-
til either of the following stopping condition is met: (i) maxiter iterations are completed; (ii) the
relative change δ(t) in the value of C across two subsequent iterations is smaller than a predefined
termination tolerance tol [Kearfott and Walster, 2000]:
δ(t) = max
ij
(
|c
(t+1)
ij − c
(t)
ij |
max(i,j) |c
(t)
ij |+ ε
)
< tol (4)
SEM was naturally obtained as a special case of GSEM by setting α = 0.0.
6.2 Experimental Details
6.2.1 Hyperparameter Tuning
GSEM hyperparameters were tuned within the grid α, β, λ ∈ {0.0, 0.01, 0.1, 1.0, 10.0, 100.0}, τ ∈
{0.0, 0.25, 0.65, 0.75, 0.85, 0.95}, with ten-fold cross-validation on the 2:1 negative-to-positive ra-
tio setting, the one originally considered in [Gottlieb et al., 2011]. Hyperparameters for SEM were
chosen likewise.
Hyperparameters optimizing average performance on validation folds were estimated to be α =
1.0, β = 0.1, λ = 0.0, τ = 0.25 for GSEM and β = 10.0, λ = 0.0 for SEM. As for model
interpretation, in order to support posterior analyses we introduced sparsity by taking the largest
values of λ not compromising model performance. Accordingly, we set λ = 0.01 for GSEM and
λ = 1.0 for SEM.
Penalty with coefficient γ = 104 was imposed on diagonal elements in every setting, and fitting
parameters were set as maxiter = 3× 103 and tol = 1× 10−3.
6.2.2 Training and Evaluation
DRRS [Luo et al., 2018], GSEM and SEM are all matrix completion models and, as thus, the whole
drug-disease association matrix is taken as input in training. At each step of cross-validation, test
and validation folds were hidden by nullifying the associated positives entries. After model fitting,
predictions over such fold entries were compared with ground truth values to evaluate performance.
PREDICT [Gottlieb et al., 2011] was learnt as a standard classification model on samples being
positive and negative drug-disease associations.
2http://bioinformatics.csu.edu.cn/resources/softs/DrugRepositioning/DRRS/index.html
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Diseases of the nervous system
Endocrine, nutritional and metabolic diseases
Neoplasms
Diseases of the musculoskeletal system and connective tissue
Diseases of the circulatory system
Diseases of the blood(-forming) organs and certain disorders involving the immune mech.
Diseases of the skin and subcutaneous tissues
Figure 2: Cosine-similarity network among disease representations learnt by GSEM. Node colour
indicates disease class. The plot has been produced via Gephi [Bastian et al., 2009] with ForceAtlas
embedding.
6.3 Model Interpretation
6.3.1 Disease Classes
We report here below in Table 1, the number of disease for each of the 11 distinct classes considered
in model interpretation.
Table 1: Disease category counts
Category Count
Diseases of the nervous system 38
Endocrine, nutritional and metabolic diseases 25
Neoplasms 25
Diseases of the musculoskeletal system and connective tissue 16
Diseases of the circulatory system 13
Diseases of the blood(-forming) organs and certain disorders involving the immune mech. 13
Diseases of the skin and subcutaneous tissue 10
Diseases of the eye and adnexa 9
Diseases of the genitourinary system 9
Mental, Behavioral and Neurodevelopmental disorders 7
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 7
Diseases of the digestive system 5
Certain infectious and parasitic diseases 5
6.3.2 Disease Similarity Network
Figure 2 depicts the disease network obtained via cosine similarity on the representations learnt
by GSEM; here we only considered sufficiently represented classes, i.e., we did not report those
associated with less than 10 diseases. From the figure, it emerges how the network presents class-
consistent clustering patterns.
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